Skip to main content

Table 2 Base-Case results

From: Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma

Strategy

Total cost

LY

QALY

ICERa

Vemurafenib + cobimetinib

353,457

2.34

1.96

Dominate

Encorafenib + binimetinib

588,988

2.64

2.22

Dominated

Dabrafenib + trametinib

455,573

2.72

2.28

325,113

Atezolizumab + vemurafenib + cobimetinib

683,381

2.83

2.38

2,247,500

  1. LY Life year; QALY Quality-adjusted life year, ICER Incremental cost-effectiveness ratio
  2. aThe ICER was compared with the next-best nondominated option